Trial Profile
A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Jan 2020 Status changed from active, no longer recruiting to completed.
- 07 Jan 2020 Planned End Date changed from 1 Aug 2020 to 31 Aug 2020.
- 07 Jan 2020 Planned primary completion date changed from 1 Aug 2019 to 31 Aug 2020.